Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Other financing activities (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Other financing activities for 9 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Other financing activities fell 29.62% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.3 million through Dec 2025, down 11.76% year-over-year, with the annual reading at $23.3 million for FY2025, 11.76% down from the prior year.
  • Other financing activities hit $2.8 million in Q4 2025 for Protagonist Therapeutics, down from $5.7 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $12.1 million in Q3 2024 to a low of -$2.3 million in Q1 2023.
  • Historically, Other financing activities has averaged $3.0 million across 5 years, with a median of $1.9 million in 2021.
  • Biggest five-year swings in Other financing activities: skyrocketed 18700.0% in 2021 and later crashed 188.39% in 2023.
  • Year by year, Other financing activities stood at $2.3 million in 2021, then tumbled by 76.36% to $553000.0 in 2022, then dropped by 6.15% to $519000.0 in 2023, then skyrocketed by 676.69% to $4.0 million in 2024, then decreased by 29.62% to $2.8 million in 2025.
  • Business Quant data shows Other financing activities for PTGX at $2.8 million in Q4 2025, $5.7 million in Q3 2025, and $2.9 million in Q2 2025.